Search hospitals > Alabama > Birmingham
University of Alabama at Birmingham Cancer Center
Claim this profileBirmingham, Alabama 35233
Global Leader in Brain Tumor
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
Conducts research for Ovarian Cancer
663 reported clinical trials
37 medical researchers
Summary
University of Alabama at Birmingham Cancer Center is a medical facility located in Birmingham, Alabama. This center is recognized for care of Brain Tumor, Breast Cancer, Lung Cancer, Cancer, Ovarian Cancer and other specialties. University of Alabama at Birmingham Cancer Center is involved with conducting 663 clinical trials across 593 conditions. There are 37 research doctors associated with this hospital, such as Victor T. Lin, Rebecca C. Arend, Amitkumar Mehta, MD, and Pankit Vachhani.Area of expertise
1Brain Tumor
Global LeaderStage IV
IDH positive
1p/19q co-deletion positive
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Victor T. LinMary Bird Perkins Cancer Center1 year of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
41 reported clinical trials
97 drugs studied
Rebecca C. ArendUniversity of Alabama at Birmingham Cancer Center2 years of reported clinical research
Studies Ovarian Cancer
Studies Cancer
18 reported clinical trials
36 drugs studied
Amitkumar Mehta, MDUniversity of Alabama at Birmingham13 years of reported clinical research
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
15 reported clinical trials
26 drugs studied
Pankit VachhaniUniversity of Alabama at Birmingham4 years of reported clinical research
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
15 reported clinical trials
23 drugs studied
Clinical Trials running at University of Alabama at Birmingham Cancer Center
Lung Cancer
Ovarian Cancer
Skin Cancer
Breast Cancer
Cancer
Kidney Cancer
Bladder Cancer
Breast cancer
Pancreatic Cancer
Uterine Cancer
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting2 awards Phase 314 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Alabama at Birmingham Cancer Center?
University of Alabama at Birmingham Cancer Center is a medical facility located in Birmingham, Alabama. This center is recognized for care of Brain Tumor, Breast Cancer, Lung Cancer, Cancer, Ovarian Cancer and other specialties. University of Alabama at Birmingham Cancer Center is involved with conducting 663 clinical trials across 593 conditions. There are 37 research doctors associated with this hospital, such as Victor T. Lin, Rebecca C. Arend, Amitkumar Mehta, MD, and Pankit Vachhani.
Where is University of Alabama at Birmingham Cancer Center located?
The UAB Comprehensive Cancer Center is situated at 1824 6th Ave S, Birmingham, AL 35233. For appointments at the UAB Women & Infants Center and Hazelrig-Salter Radiation Oncology Center, valet parking is offered at the entrance, with an alternative to self-park in the deck located at 4th Avenue and 18th Street South. The main parking deck for patients and guests attending UAB Hospital is also at 4th Avenue and 18th Street South.
Who should I call to ask about financial aid or insurance network?
For financial assistance at the University of Alabama at Birmingham (UAB) Cancer Center, contact UAB Medicine Patient Billing Solutions at (205) 934-6400 or toll-free at (888) 309-8435. For insurance inquiries, call the main switchboard at (205) 934-4011. Hearing-impaired individuals can reach out via the TDD line at (205) 934-4642.
What insurance does University of Alabama at Birmingham Cancer Center accept?
The University of Alabama at Birmingham Cancer Center accepts various insurance plans, including Blue Cross and Blue Shield of Alabama, Viva Health, and Blue Cross/Blue Shield. Accepted plans include Viva UAB, Viva Access, and Blue Cross/Blue Shield's nationwide PPO network, covering one annual eye exam and offering student and sabbatical riders for out-of-network services. Additionally, the University of Alabama at Birmingham National Alumni Society offers life, health, travel, and other insurance plans for alumni and their families.
What awards or recognition has University of Alabama at Birmingham Cancer Center received?
The University of Alabama at Birmingham Comprehensive Cancer Center is the only National Cancer Institute-designated comprehensive cancer center in a six-state area, serving Alabama, Arkansas, Georgia, Louisiana, Mississippi, and South Carolina. It is renowned for its excellence in cancer research and patient care, earning rankings among the top institutions in the Southeast and the nation by U.S. News. Additionally, it has been recognized as a Magnet-designated organization by the American Nurses Credentialing Center Magnet Recognition Program® for the fifth consecutive time and named a Health Care Equality Leader by the Human Rights Campaign Foundation.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.